Value of Machine Learning with Multiphases CE-MRI Radiomics for Early Prediction of Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Invasive Breast Cancer
Qin Li,Qin Xiao,Jianwei Li,Zhe Wang,He Wang,Yajia Gu
DOI: https://doi.org/10.2147/CMAR.S304547
2021-06-28
Cancer Management and Research
Abstract:Qin Li, 1, 2, &ast Qin Xiao, 1, 2, &ast Jianwei Li, 2, 3 Zhe Wang, 4, 5 He Wang, 4, 5 Yajia Gu 1, 2 1 Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; 3 Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; 4 Shanghai Center for Mathematical Sciences, Fudan University, Shanghai, People's Republic of China; 5 Human Phenome Institute, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yajia Gu; He Wang Tel +8618017312040 Fax +862164174774 Email ; Background: To assess the value of radiomics based on multiphases contrast-enhanced magnetic resonance imaging (CE-MRI) for early prediction of pathological complete response (pCR) to neoadjuvant therapy (NAT) in patients with human epithelial growth factor receptor 2 (HER2) positive invasive breast cancer. Methods: A total of 127 patients with newly diagnosed primary HER2 positive invasive breast cancer underwent CE-MRI before NAT and performed surgery after NAT. Radiomic features were extracted from the 1 st postcontrast CE-MRI phase (CE 1 ) and multi-phases CE-MRI (CE m ),respectively. With selected features using a forward stepwise regression, 23 machine learning classifiers based on CE 1 and CE m were constructed respectively for differentiating pCR and non-pCR patients. The performances of classifiers were assessed and compared by their accuracy, sensitivity, specificity and AUC (area under curve). The optimal machine learning classification was used to discriminate pCR vs non-pCR in mass and non-mass groups, uni-focal and unilateral multi-focal groups, respectively. Results: For the task of pCR classification, 6 radiomic features from CE 1 and 6 from CE m were selected for the construction of machine learning models, respectively. The linear SVM based on CE m outperformed the logistic regression model using CE 1 with an AUC of 0.84 versus 0.69. In mass and non-mass enhancement groups, the accuracy of linear SVM achieved 84% and 76%. Whereas in unifocal and unilateral multifocal cases, 79% and 75% accuracy were achieved by linear SVM. Conclusion: Multiphases CE-MRI imaging may offer more heterogeneity information in the tumor and provide a non-invasive approach for early prediction of pCR to NAT in patients with HER2-positive invasive breast cancer. Keywords: radiomics, breast cancer, neoadjuvant therapy, machine learning, magnetic resonance imaging HER2 (human epithelial growth factor receptor 2) positive breast cancer (non-luminal) is defined as HER2-positive and hormone receptor (HR)-negative tumor. It has high malignancy, more recurrence and poor prognosis, but is sensitive to neoadjuvant therapy (NAT, chemotherapy combined anti-HER2 therapy) 1 , 2 which is widely used in HER2 positive breast cancer. 3–5 NAT could improve the disease-free and overall survival, therefore the pathologic complete response (pCR) to NAT has been proposed as a prognostic marker in HER2 positive breast cancer patients. 6–9 Nevertheless, only about 40% of the patients could achieve pCR after the completion of NAT. Predicting pCR before NAT is desirable for identifying patients who will not benefit from NAT. Identification of pCR can only be confirmed by histopathological specimens which is traumatic and may not reflect the heterogeneity of the entire tumor. Thus, a method to predict pCR earlier and noninvasively remains a major challenge. Compared with mammography and ultrasound, breast magnetic resonance imaging (MRI) was confirmed as the most reliable imaging tool for evaluating the response of tumor to chemotherapy. 10 , 11 Many imaging modality of MRI, such as T2WI (T2 weighted imaging), DWI (diffusion weighted imaging) and CE (contrast enhancement)-MRI, had been proposed to evaluate the response to NAT in patients with breast cancer. 12 , 13 Besides, CE-MRI is sensitive to perfusion, permeability of tissue microvascular and angiogenic changes and has been identified as the most sensitive method for prediction of treatment response to -Abstract Truncated-
oncology